BUZZ-Esperion rises as partner launches cholesterol drug in Japan
Shares of drug developer Esperionrise 1.7% to $3 premarketCompany says it will receive a $90 million payment after its Japanese partner, Otsuka Pharmaceutical, launched cholesterol-lowering drug Nexletol in Japan.Otsuka received national approval to sell Nexletol for patients with high cholesterol and certain inherited cholesterol disorders, ESPR saysESPR eligible for additional milestones and 15%-30% royalties on Japan salesJapan is third-largest market for cardiovascular prevention, ESPR saysUp to last close, shares up ~34% YTD
Shares of drug developer Esperion (ESPR.O) rise 1.7% to $3 premarket
Company says it will receive a $90 million payment after its Japanese partner, Otsuka Pharmaceutical, launched cholesterol-lowering drug Nexletol in Japan.
Otsuka received national approval to sell Nexletol for patients with high cholesterol and certain inherited cholesterol disorders, ESPR says
ESPR eligible for additional milestones and 15%-30% royalties on Japan sales
Japan is third-largest market for cardiovascular prevention, ESPR says
Up to last close, shares up ~34% YTD
